Perjeta (Pertuzumab) vs Trodelvy (sacituzumab govitecan-hziy)
Perjeta (Pertuzumab) vs Trodelvy (sacituzumab govitecan-hziy)
Perjeta (pertuzumab) is a monoclonal antibody designed to target the HER2 receptor, which is overexpressed in some types of breast cancer, and it is often used in combination with other therapies for the treatment of HER2-positive breast cancer. Trodelvy (sacituzumab govitecan-hziy), on the other hand, is an antibody-drug conjugate that targets the Trop-2 receptor and is used to treat triple-negative breast cancer, which lacks the three most common types of receptors known to fuel most breast cancer growth—estrogen, progesterone, and the HER-2 gene. The choice between Perjeta and Trodelvy would largely depend on the specific characteristics of the breast cancer being treated, including receptor status and previous treatments, and should be made in consultation with an oncologist.
Difference between Perjeta and Trodelvy
Metric | Perjeta (Pertuzumab) | Trodelvy (sacituzumab govitecan-hziy) |
---|---|---|
Generic name | Pertuzumab | Sacituzumab govitecan-hziy |
Indications | HER2-positive breast cancer | Metastatic triple-negative breast cancer, Urothelial cancer |
Mechanism of action | HER2/neu receptor antagonist | Antibody-drug conjugate targeting Trop-2 |
Brand names | Perjeta | Trodelvy |
Administrative route | Intravenous | Intravenous |
Side effects | Diarrhea, rash, nausea, fatigue, mucosal inflammation, etc. | Neutropenia, diarrhea, nausea, fatigue, anemia, etc. |
Contraindications | Hypersensitivity to pertuzumab or its excipients | Hypersensitivity to sacituzumab govitecan-hziy or its excipients |
Drug class | Monoclonal antibody | Antibody-drug conjugate |
Manufacturer | Genentech (Roche) | Gilead Sciences |
Efficacy
Efficacy of Perjeta (Pertuzumab) in Breast Cancer
Perjeta (pertuzumab) is a monoclonal antibody that targets the HER2 receptor, a protein overexpressed in some types of breast cancer. Pertuzumab is designed to prevent the HER2 receptor from pairing with other HER receptors on the surface of cancer cells, which can inhibit tumor growth. It is often used in combination with trastuzumab and chemotherapy. Clinical trials have demonstrated that the addition of pertuzumab to standard therapy can significantly improve progression-free survival and overall survival in patients with HER2-positive metastatic breast cancer. The CLEOPATRA study, a pivotal phase III trial, showed that patients receiving pertuzumab in combination with trastuzumab and docetaxel had a median progression-free survival that was 6.1 months longer than those receiving the standard therapy alone.
Efficacy of Trodelvy (Sacituzumab Govitecan-hziy) in Breast Cancer
Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate that targets the Trop-2 antigen, which is expressed in the majority of breast cancers. The drug links an anti-Trop-2 antibody with a chemotherapy agent, allowing for direct delivery of the chemotherapeutic to the cancer cells. This targeted approach helps to minimize the impact on healthy cells. Trodelvy has shown a significant impact on patients with metastatic triple-negative breast cancer (TNBC), a particularly aggressive and difficult-to-treat form of the disease. In a phase III trial (ASCENT), sacituzumab govitecan-hziy demonstrated a median progression-free survival of 5.6 months compared to 1.7 months with chemotherapy, and an overall survival of 12.1 months compared to 6.7 months, respectively.
Comparative Efficacy in Different Subtypes of Breast Cancer
It's important to note that the efficacy of Perjeta and Trodelvy varies significantly based on the breast cancer subtype. Perjeta is specifically indicated for HER2-positive breast cancer, a subtype where HER2 protein overexpression is a driving factor in cancer progression. On the other hand, Trodelvy is used in the treatment of triple-negative breast cancer, which lacks the expression of estrogen receptors, progesterone receptors, and HER2, and therefore does not respond to hormonal therapy or therapies targeting HER2. The targeted mechanisms of action of these drugs underpin their efficacy in these distinct patient populations.
Conclusion
In conclusion, both Perjeta and Trodelvy have shown to be effective in their respective indications for breast cancer treatment. Perjeta, in combination with other therapies, has improved outcomes for patients with HER2-positive breast cancer, while Trodelvy has emerged as a significant advancement for patients with metastatic triple-negative breast cancer. The use of these targeted therapies represents a shift towards personalized medicine in oncology, where treatment is increasingly tailored to the specific characteristics of a patient's cancer.
Regulatory Agency Approvals
Perjeta
Trodelvy
Access Perjeta or Trodelvy today
If Perjeta or Trodelvy are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us